Everyone Wins From This Acquisition

Shares of generic drugmaker Actavis have gone on a huge run lately, which has caught the attention of would-be acquirers. But instead of getting gobbled up, Actavis went on the offense and will buy a spec pharma for $8.5 billion.

In this video, health-care analyst David Williamson discusses the merits of two competing deals for Actavis, one from generic drug company Mylan and another from serial acquirer Valeant. He also talks about why Actavis' purchase of Warner Chilcott worked out for the best for all parties involved.

Another topic health care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more. 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2442572, ~/Articles/ArticleHandler.aspx, 7/31/2014 2:15:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 0.12 0.01%
NASD 4,462.90 20.20 0.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/30/2014 4:06 PM
ACT $215.55 Up +0.70 +0.33%
ACTAVIS CAPS Rating: ****
MYL $50.55 Up +0.15 +0.30%
Mylan Inc. CAPS Rating: ****
VRX $125.83 Up +2.13 +1.72%
Valeant Pharmaceut… CAPS Rating: ***
WCRX $0.00 Down +0.00 +0.00%
Warner Chilcott Lt… CAPS Rating: ***

Advertisement